Corresponding Author: Miguel Valderrábano, MD, Division of Cardiac Electrophysiology, Department of Cardiology, Houston Methodist Hospital, 6550 Fannin St, Ste 1801, Houston, TX 77030 (mvalderrabano@houstonmethodist.org).
Accepted for Publication: August 10, 2020.
Author Contributions: Drs Valderrábano and Peterson had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Valderrábano, Peterson, Schurmann, Natale, Dave, Afshar, Morillo.
Acquisition, analysis, or interpretation of data: Valderrábano, Peterson, Swarup, Schurmann, Makkar, Doshi, DeLurgio, Athill, Ellenbogen, Koneru, Dave, Giorgberidze, Afshar, Guthrie, Bunge, Kleiman.
Drafting of the manuscript: Valderrábano, Peterson, Schurmann, Athill, Ellenbogen, Afshar, Guthrie.
Critical revision of the manuscript for important intellectual content: Peterson, Swarup, Schurmann, Makkar, Doshi, DeLurgio, Athill, Ellenbogen, Natale, Koneru, Dave, Giorgberidze, Bunge, Morillo, Kleiman.
Statistical analysis: Valderrábano, Peterson, Morillo.
Obtained funding: Valderrábano.
Administrative, technical, or material support: Valderrábano, Schurmann, Makkar, DeLurgio, Ellenbogen, Giorgberidze, Guthrie, Bunge.
Supervision: Valderrábano, Natale, Giorgberidze, Afshar, Bunge, Morillo.
Other—data collection and review: Swarup.
Conflict of Interest Disclosures: Dr Valderrábano reported serving as a consultant for Biosense Webster; a speaker for Boston Scientific; research support member for Circa Scientific; and consultant and speaker for Baylis Medical. Dr Swarup reported providing research and consulting services to Biosense Webster, Boston Scientific, and Abbott outside the submitted work. Dr Athill reported receiving grants and other funding from Methodist Hospital Research Institute during the conduct of the study and grants and personal fees from Boston Scientific and Abbott Laboratories; grants from Biosense Webster; and personal fees from Janssen Pharmaceutical and Zoll Medical outside the submitted work. Dr Natale reported receiving personal fees from Biosense Webster, Biotronik, Medtronic, Boston Scientific, and Abbott during the conduct of the study and outside the submitted work. Dr Dave reported serving as a consultant to Abbott outside the submitted work. Dr Bunge reported receiving grants from Houston Methodist Research Institute during the conduct of the study. Dr Morillo reported receiving personal fees from Medtronic and serving as a member of the steering committee of the STAR AF trials for Abbott outside the submitted work. No other disclosures were reported.
Funding/Support: This study was funded by grant R01HL115003 from the National Institutes of Health/National Heart, Lung, and Blood Institute. Additional support came from Charles Burnett III and Lois and Carl Davis Centennial Chair endowments (Dr Valderrábano) and Houston Methodist Research Institute.
Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 3.
1.Calkins
H , Hindricks
G , Cappato
R ,
et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.
Heart Rhythm. 2017;14(10):e275-e444. doi:
10.1016/j.hrthm.2017.05.012PubMedGoogle Scholar 3.Dixit
S , Marchlinski
FE , Lin
D ,
et al. Randomized ablation strategies for the treatment of persistent atrial fibrillation: RASTA study.
Circ Arrhythm Electrophysiol. 2012;5(2):287-294. doi:
10.1161/CIRCEP.111.966226PubMedGoogle Scholar 4.Verma
A , Jiang
CY , Betts
TR ,
et al; STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation.
N Engl J Med. 2015;372(19):1812-1822. doi:
10.1056/NEJMoa1408288PubMedGoogle Scholar 5.Lee
SH , Tai
CT , Hsieh
MH ,
et al. Predictors of non-pulmonary vein ectopic beats initiating paroxysmal atrial fibrillation: implication for catheter ablation.
J Am Coll Cardiol. 2005;46(6):1054-1059. doi:
10.1016/j.jacc.2005.06.016PubMedGoogle Scholar 10.Valderrábano
M , Chen
HR , Sidhu
J , Rao
L , Ling
Y , Khoury
DS . Retrograde ethanol infusion in the vein of Marshall: regional left atrial ablation, vagal denervation and feasibility in humans.
Circ Arrhythm Electrophysiol. 2009;2(1):50-56. doi:
10.1161/CIRCEP.108.818427PubMedGoogle Scholar 11.Dave
AS , Báez-Escudero
JL , Sasaridis
C , Hong
TE , Rami
T , Valderrábano
M . Role of the vein of Marshall in atrial fibrillation recurrences after catheter ablation: therapeutic effect of ethanol infusion.
J Cardiovasc Electrophysiol. 2012;23(6):583-591. doi:
10.1111/j.1540-8167.2011.02268.xPubMedGoogle Scholar 12.Báez-Escudero
JL , Keida
T , Dave
AS , Okishige
K , Valderrábano
M . Ethanol infusion in the vein of Marshall leads to parasympathetic denervation of the human left atrium: implications for atrial fibrillation.
J Am Coll Cardiol. 2014;63(18):1892-1901. doi:
10.1016/j.jacc.2014.01.032PubMedGoogle Scholar 13.Pambrun
T , Denis
A , Duchateau
J ,
et al. MARSHALL bundles elimination, pulmonary veins isolation and lines completion for anatomical ablation of persistent atrial fibrillation: MARSHALL-PLAN case series.
J Cardiovasc Electrophysiol. 2019;30(1):7-15. doi:
10.1111/jce.13797PubMedGoogle Scholar 14.Valderrábano
M , Peterson
LE , Bunge
R ,
et al. Vein of Marshall ethanol infusion for persistent atrial fibrillation: VENUS and MARS clinical trial design.
Am Heart J. 2019;215:52-61. doi:
10.1016/j.ahj.2019.04.022PubMedGoogle Scholar 15.Valderrábano
M , Liu
X , Sasaridis
C , Sidhu
J , Little
S , Khoury
DS . Ethanol infusion in the vein of Marshall: adjunctive effects during ablation of atrial fibrillation.
Heart Rhythm. 2009;6(11):1552-1558. doi:
10.1016/j.hrthm.2009.07.036PubMedGoogle Scholar 16.Tilz
RR , Rillig
A , Thum
AM ,
et al. Catheter ablation of long-standing persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy.
J Am Coll Cardiol. 2012;60(19):1921-1929. doi:
10.1016/j.jacc.2012.04.060PubMedGoogle Scholar 17.Gillinov
AM , Gelijns
AC , Parides
MK ,
et al; CTSN Investigators. Surgical ablation of atrial fibrillation during mitral-valve surgery.
N Engl J Med. 2015;372(15):1399-1409. doi:
10.1056/NEJMoa1500528PubMedGoogle Scholar 19.Fink
T , Schlüter
M , Heeger
CH ,
et al. Stand-alone pulmonary vein isolation versus pulmonary vein isolation with additional substrate modification as index ablation procedures in patients with persistent and long-standing persistent atrial fibrillation: the randomized alster-lost-af trial (ablation at St G0 rg Hospital for long-standing persistent atrial fibrillation).
Circ Arrhythm Electrophysiol. 2017;10(7):e005114. doi:
10.1161/CIRCEP.117.005114PubMedGoogle Scholar 20.Kim
JS , Shin
SY , Na
JO ,
et al. Does isolation of the left atrial posterior wall improve clinical outcomes after radiofrequency catheter ablation for persistent atrial fibrillation? a prospective randomized clinical trial.
Int J Cardiol. 2015;181:277-283. doi:
10.1016/j.ijcard.2014.12.035PubMedGoogle Scholar 21.Tamborero
D , Mont
L , Berruezo
A ,
et al. Left atrial posterior wall isolation does not improve the outcome of circumferential pulmonary vein ablation for atrial fibrillation: a prospective randomized study.
Circ Arrhythm Electrophysiol. 2009;2(1):35-40. doi:
10.1161/CIRCEP.108.797944PubMedGoogle Scholar 22.Lee
JM , Shim
J , Park
J ,
et al; POBI-AF Investigators. The electrical isolation of the left atrial posterior wall in catheter ablation of persistent atrial fibrillation.
JACC Clin Electrophysiol. 2019;5(11):1253-1261. doi:
10.1016/j.jacep.2019.08.021PubMedGoogle Scholar